Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-609-3 | CAS number: 65-45-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Skin: not sensitising, LLNA, OECD 429, Vogel 2010
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, guideline study, no restrictions, fully adequate for assessment.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8 - 12 weeks
- Weight at study initiation: 15 - 25 g
- Housing:single caging
- Diet (e.g. ad libitum): pelleted standard diet (Harlan Laboratories GmbH, 33178 Borchen), ad libidum
- Water (e.g. ad libitum): tap water, (Gemeindewerke, 64380 Rossdorf), ad libitum
- Acclimation period: At least 5 days prior to the start of dosing under test conditions after health examination. Only animals without any visible signs of illness will be used for the study
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 + 2°C
- Humidity (%): 45-65%
- Photoperiod (hrs dark / hrs light): artificial light 6:00 a.m. - 6:00 p.m.
- Vehicle:
- dimethylformamide
- Concentration:
- 10, 25, and 50% (w/v)
- No. of animals per dose:
- 4
- Details on study design:
- VEHICLE AND DOSE SELECTION
A solubility experiment was performed according to the recommendations given by OECD 429. The highest test item concentration, which could be technically used was a 50% (w/v) solution in dimethylformamide (DMF) after vortexing and warming to 37°C. The vehicle was chosen due to its solubilisation properties.
To determine the highest non-irritant test concentration that did at the same time not induce signs of systemic toxicity,a pre-test was performed in two animals. Two mice were treated by (epidermal) topical application to the dorsal surface of each ear with test item concentrations of 25 and 50% once daily each on three consecutive days. Furthermore, prior to the first application of the test item and before sacrifice the body weight was determined. Both animals gained weight during the course of the pre-test.
In the pre-test clinical signs were recorded within 1 hour and 24±4 hours after each application as well as on day 7. At the tested concentrations the animals did not show any signs of local irritation or systemic toxicity.
Thus the test item in the main study was assayed at 10, 25, and 50% (w/v). The top dose is the highest technically achievable concentration whilst avoiding systemic toxicity and excessive local irritation.
MAIN TEST
TOPICAL APPLICATION
Each test group of mice was treated by topical (epidermal) application to the dorsal surface of each ear (left and right) with different test item concentrations of 10, 25, and 50% (w/v) in dimethylformamide. The application volume, 25 µl, was spread over the entire dorsal surface (Æ~8 mm) of each ear once daily for 3 consecutive days. A further group of mice was treated with an equivalent volume of the vehicle alone (control animals).
ADMINISTRATION AND DETERMINATION OF INCORPORATED 3H-METHYL THYMIDINE
Five days after the first topical application, all mice were administered with 250 µl of 81.7 µCi/mL3HTdR (corresponds to 20.4 µCi3HTdR per mouse) by intravenous injection via a tail vein. Approximately five hours after injection, the mice were sacrificed and the draining of auricular lymph nodes were excised and pooled per group. Single cell suspensions of lympg node cells were prepared from pooled lymph nodes, which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3HTdR measured in a beta-scintilation counter.
INTERPRETATION OF RAW DATA
The proliferative response of lymph node cells is expressed as the number of radioactive disintegrations per minute per lymph node (DPM/node) and as the ratio of 3HTdR incorporated into lymph node cells of test lymph nodes relative to that recorded for control lymph nodes (Stimulation Index; S.I.). Before DPM/node values were determined, mean scintillation-background DPM was subtracted from test and control raw data. A test item is regarded as a sensitiser in the LLNA if the following criteria are fulfilled: First, that exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than that recorded in control mice, as indicated by the stimulation index.
Second, that the data are compatible with a conventional dose response, although allowance must be made (especially at high topical concentrations) for either local toxicity or immunological suppression.
OBSERVATIONS
In addition to the sensitising reactions the following observations and data were recorded during the test and observation period:
Mortality / Viability: once daily (week day) from experimental start to necropsy.
Body weights: prior to the first application and prior to treatment with3HTdR.
Clinical signs (local / systemic): In the pre-test clinical signs were recorded within 1 hour and 24±4 hours after each application as well as on day 7. In the main experiment clinical signs were recorded within 1 hour and 24±4 hours after the first and second application (days 1 and 2) as well as on the day of preparation (day 6). Especially the treatment sites were observed carefully. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- The mean values and standard deviations were calculated in the body weight tables.
- Positive control results:
- Experiment performend in May 2010, 5, 10, and 25% alpha-Hexylcinnamaldehyde in acetone:olive oil (4+1) yielded a S.I. of 2.04, 3.41, and 6.14, respectively. The EC3 value calculated was 8.5%
- Parameter:
- SI
- Value:
- 1.56
- Test group / Remarks:
- 10% test item concentration (w/v)
- Remarks on result:
- other: see table below
- Parameter:
- SI
- Value:
- 1.29
- Test group / Remarks:
- 25% test item concentration (w/v)
- Remarks on result:
- other: see table below
- Parameter:
- SI
- Value:
- 1.32
- Test group / Remarks:
- 50% test item concentration (w/v)
- Remarks on result:
- other: see table below
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: see table below
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information
- Conclusions:
- The test item was not a skin sensitiser under the described conditions.
- Executive summary:
In order to study the possible contact allergenic potential of the substance, 3 groups each of 4 female mice were treated daily with the test item at concentrations of 10, 25, and 50% (w/v) in dimethylformamide by topical application to the dorsum of each ear (left and right) for 3 consecutive days. A control group of 4 mice was treated with the vehicle (dimethylformamide) only. Five days after the first topical application the mice were injected intravenously into a tail vein with radio-labelled thymidine (3H-methyl thymidine). Approximately 5 hours after intravenous injection, the mice were sacrificed, the draining auricular lymph nodes excised and pooled per group. Single cell suspensions of lymph node cells were prepared from pooled lymph nodes, which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of3H-methyl thymidine measured in ab-scintillation counter.
All treated animals survived the scheduled study period and no signs of toxicity were observed.
A test item is regarded as a sensitiser in the LLNA if the exposure to one or more test concentration resulted in 3-fold or greater increase in incorporation of3HTdR compared with concurrent controls, as indicated by the Stimulation Index (S.I.). The estimated concentration of test item required to produce a S.I. of 3 is referred to as the EC3 value.
In this study Stimulation Indices of 1.56, 1.29, and 1.32 were determined with the test item at concentrations of 10, 25, and 50% (w/v) in dimethylformamide. A dose response was not observed.
The EC3 value could not be calculated, since none of the tested concentrations induced an S.I. greater than 3.
Reference
Calculation of Results
Since the lymph nodes of the animals of a dose group were pooled, the number of radioactive disintegrations per minute per lymph node (DPM/node) was determined by dividing the measured DPM-value by the number of lymph nodes pooled (8 lymph nodes). Before DPM/node values were determined, mean scintillation-background DPM was subtracted from test and control raw data. For the control group (vehicle group), a DPM/node value of 336.6 was determined whereas DPM/node values of 523.4, 435.8, and 444.8 were determined for the test item groups with test item concentrations of 10, 25, and 50% (w/v), respectively. The Stimulation Indices calculated for these groups were 1.56 (at a test item concentration of 10%), 1.29 (at a test item concentration of 25%) and 1.32 (at a test item concentration of 50%) (see Table 2). The EC3 value could not be calculated, since none of the tested concentrations induced an S.I. greater than 3.
Viability / Mortality
No deaths occurred during the study period.
Clinical Signs
No symptoms of local toxicity at the ears of the animals and no systemic findings were observed during the study period.
Body Weights
The body weight of the animals, recordedprior to the first application and prior to treatment with3HTdR, was within the range commonly recorded for animals of this strain and age
Summary of Results
Test item concentration % (w/v) |
Group |
Measurement DPM |
Calculation |
Result |
||
DPM-BGa) |
number of lymph nodes |
DPM per lymph nodeb) |
S.I. |
|||
--- |
BG I |
20 |
--- |
--- |
--- |
--- |
--- |
BG II |
17 |
--- |
--- |
--- |
--- |
--- |
1 |
2711 |
2693 |
8 |
336.6 |
1.00 |
10 |
2 |
4206 |
4188 |
8 |
523.4 |
1.56 |
25 |
3 |
3505 |
3487 |
8 |
435.8 |
1.29 |
50 |
4 |
3577 |
3559 |
8 |
444.8 |
1.32 |
BG = Background (1 mL 5% trichloroacetic acid) in duplicate
1 = Control Group
2-4= Test Groups
S.I. = Stimulation Index
a) = The mean value was taken from the figures BG I and BG II
b) = Since the lymph nodes of the animals of a dose group were pooled, DPM/node was determined by dividing the measured value by the number of lymph nodes pooled
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Two published QSAR results for salicylamide were available, both were unvalidated experimental models. Dimitrov et al (2005) predicted the substance to be sensitising, while Magee et al (2000) predicted it to be non-sensitising. Both results were discarded as being unreliable. However, both studies refer to an experimental result of non-sensitising in Cronin et al. (1994), SAR and QSAR in Environmental Research 2, 159 -179. The original Cronin paper contains no reference to salicylamide (but does refer to salicylanilide - non-sensitising). Therefore this result also had to be discarded as unreliable.
A single experimental study was available which was conducted under GLP and according to OECD guideline 429. The result as non-sensitising is considered to be relevant, reliable, and adequate for risk assessment, classification and labelling.
Justification for selection of skin sensitisation endpoint:
GLP compliant, guideline study, no restrictions, fully adequate for assessment.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The results from a mouse local lymph node assay indicate the substance is not a skin sensitiser. As a result the substance does not meet the criteria for classification according to Regulation (EC) No. 1272/2008, Part 3, 3.4.2.2.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.